Case Report: Prolonged Anorexia With Nausea Caused by Immune Checkpoint Inhibitors for Malignant Melanoma Treated Using Kampo Medicines Bukuryoingohangekobokuto and Ninjin’yoeito

Shin Takayama*, Ryutaro Arita and Tadashi Ishii

Department of Education and Support for Regional Medicine (General Medicine and Kampo Medicine), Tohoku University Hospital, Sendai, Japan

Immune checkpoint inhibitors (ICIs) are indicated for several cancers, including malignant melanoma. Anorexia and nausea resulting in malnutrition are side effects of ICIs. In such cases, conventional drugs are used for symptom relief, but the symptoms may persist. We report a case of advanced malignant melanoma with prolonged anorexia and nausea, which occurred after nivolumab administration, and was successfully treated using Kampo medicines. A 75-year-old man with nasal bleeding visited our hospital. A nasal scope revealed an obstructive tumor in the left nasal concha. Tissue biopsy showed malignant melanoma, and computed tomography showed metastasis to the liver and bone. Thus, the patient was diagnosed with stage IV malignant melanoma. He received radiotherapy (30 Gy) and nivolumab with ipilimumab four times, followed by nivolumab administration alone. During the administration of nivolumab, he complained of severe anorexia and nausea, with a numeric rating scale (no symptoms, 0; severe symptoms, 10) score of 10. He could not consume food because of these symptoms, even after nivolumab administration was discontinued. His blood pressure was 92/59 mmHg, his performance status (no fatigue, 0; bedridden or disabled, 4) was 4, and his body weight gradually decreased from 60 to 39 kg in a month. The patient showed malnutrition and dehydration and experienced anxiety and depression. Nivolumab was terminated, and conventional symptomatic drugs were prescribed, but the symptoms persisted. We then prescribed 9.0 g/day of ninjin’yoeito (TJ-108, Tsumura and Co.) to allow recovery from anorexia and subsequently added bukuryoingohangekobokuto (TJ-116, Tsumura and Co.) to treat the persistent nausea. After treatment with these two Kampo medicines, the patient’s appetite gradually recovered. Along with the recovery of nutritional status, his PS improved to 0, his anxiety and depressive state improved, and his body weight increased to 60 kg. The patient remained in good condition without cancer recurrence. The patient’s clinical course shows the usefulness of Kampo medicine as supportive care for symptom relief and maintenance of nutritional and mental status during cancer treatment.

Keywords: immune checkpoint inhibitors, side effect, anorexia, recover, kampo medicine
INTRODUCTION

Several immune checkpoint inhibitors (ICIs) have been developed to treat cancers, including malignant melanoma. Side effects of nivolumab have been reported, including appetite loss and nausea (JAPIC, 2014), with an incidence of >5.0%. Anorexia and nausea, resulting in poor nutritional status, are general problems associated with treatment using ICIs. Conventional drugs for symptom relief are used in these cases; however, symptoms are occasionally refractory to such treatment. Prolonged appetite loss due to nausea causes malnutrition, which leads to frailty, and influences mental status.

In contrast, the use of Kampo medicines for patients with cancer was reported to be >70% among physicians in core cancer treatment hospitals (Ito et al., 2012). The application of Kampo medicines, including ginseng, such as rikkunshito (RKT), has been reported in the treatment of anorexia as a side effect of cancer treatment (Yoshiya et al., 2020). We previously reported long-term survival and improvement in quality of life in patients with advanced cancer, including pancreatic cancer, brain cancer, and esophageal cancer, which was supported with Kampo medicines (Shimizu et al., 2021a; Shimizu et al., 2021b; Suzuki et al., 2021; Takayama and Ishii, 2022). Ninjin’yoito (NYT) allows recovery from anorexia with frailty, and bukuryoingohangekobokuto (BRGHT) is used for persistent nausea with anxiety.

Kampo medicines is used according to slight and minor symptoms, considering the patient’s body composition, constitution, and characteristics. According to symptoms and physical findings, RKT is used for the treatment of anorexia with qi (energy) deficiency and fluid retention; NYT is used to treat anorexia and malnutrition with qi deficiency and blood deficiency; and BRGHT is used to treat anorexia, nausea, vomiting, and anxiety with qi deficiency, qi counterflow, phlegm, and dampness in the traditional medicine setting.

Here, we report a case of advanced malignant melanoma with severe appetite loss and nausea, which occurred after ICIs administration and was recovered through Kampo medicine.

CASE DESCRIPTION

A 75-year-old man with a history of myocardial infarction and habituation to smoking complained of nasal bleeding and visited our hospital. A nasal scope revealed an obstructive tumor in the left nasal concha (Figure 1A). Tissue biopsy showed malignant melanoma, and computed tomography (Figure 2A) showed the obstructed tumor at the left nasal concha with metastases in the liver and bone; thus, he was diagnosed with stage IV malignant melanoma. Programmed death-ligand 1 (PD-L1) test using a biopsy showed positive results, suggesting that anti-cancer drugs and ICIs could effectively treat the advanced-stage malignant melanoma. The patient received radiotherapy (30 Gy) and nivolumab with ipilimumab four times, followed by the sole administration of nivolumab. Subsequently, the patient complained of severe anorexia with nausea, with a numerical rating scale (NRS; no symptoms, 0; severe symptoms, 10) score of 10. He also complained of taste disorder. The patient was unable to eat because of these symptoms. At the first visit to our outpatient clinic, his blood pressure was 92/59 mmHg, and his performance status (PS; no fatigue, 0; bedridden or disabling, 4) (Date, 1999) was 4. His body weight gradually decreased from 60 to 39 kg in a month. His body mass index decreased to 15.7, with a blood test showing total protein (TP) 6.0 g/dL, albumin (Alb) 3.2 g/dL, creatinine (Cr) 1.38 mg/dL, and lymphocyte count 1780/μL. The patient was positive for malnutrition and dehydration, and he experienced anxiety and depression. Anorexia, nausea, and renal failure were suspected to be adverse reactions to the ICIs. Hence, nivolumab was terminated; but the symptoms persisted. Conventional drugs, such as mosapride citrate hydroxide, metoclopramide, and lansoprazole, were prescribed, but they did not eliminate the symptoms. Despite the tumor reduction (Figures 1B, 2B), his PS, mental status, and quality of life decreased after cancer remission.
According to traditional medicine diagnosis, persistent nausea and anorexia, with a weak pulse and hypochondriac stuffiness, showed qi deficiency with fluid retention. Because his pulse remained weak and water brash from the stomach to esophagus persisted, indicating qi deficiency, qi counterflow, phlegm, and dampness in the traditional medicine setting, we changed RKT to BRIGHT (TJ-116, Tsumura and Co., see STORK http://mpdb.nibiohn.go.jp/stork/) to treat the persistent anorexia, nausea, vomiting, and anxiety. After taking these two Kampo medicines, his appetite gradually recovered, and nutritional status indicators such as TP, Alb, and body weight gradually increased. His PS improved from 4 to 0, and his anxiety and depressive state also improved, with his body weight returning to 60 kg. Figure 3 shows the clinical course of the treatment.

After the re-administration of nivolumab under Kampo treatment, the patient remained in good condition, with no cancer recurrence.

DISCUSSION

Recently, ICIs, such as human monoclonal anti-human PD-1 antibody, have been developed for several cancers, including malignant melanoma. Anorexia, nausea, and poor nutritional status are side effects of cancer treatment, including the use of ICIs. Prolonged anorexia and nausea cause malnutrition and mental disorders, leading to frailty during cancer treatment. Conventional treatment is used as supportive care to relieve these symptoms, but the symptoms occasionally persist. Delayed or prolonged effects and adverse reactions with ICIs have also been known. Furthermore, severe anorexia might be induced by combining nivolumab and ipilimumab rather than nivolumab alone.

In Japan, physicians can prescribe 148 types of Kampo medicines under the national health insurance system. Hospitalized patients undergoing cancer treatment via gastrointestinal and gynecological surgery receive several Kampo medicines (Sugimine et al., 2021). Recently, randomized controlled trials (RCTs) showed the efficacy and safety of Kampo medicines, including in cancer treatment (Motoo et al., 2021).

Frailty and cachexia related to cancer are serious problems. Anamorelin hydrochloride is a ghrelin mimetic agent for the treatment of cancer cachexia. However, its indication is limited to patients with unresectable advanced or recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. Anamorelin hydrochloride is not indicated in cases of malignant melanoma, such as the present case. Supportive care during cancer treatment, including using Kampo medicine, is occasionally indicated to relieve symptoms such as fatigue, nausea, appetite loss, constipation, diarrhea, and abdominal pain. Table 1 shows the list of Kampo medicines, including ginseng, for symptom relief in cancer treatment.

According to traditional medicine diagnosis, persistent nausea and anorexia, with a weak pulse and hypochondriac stuffiness, showed qi deficiency with fluid retention. We prescribed 7.5 g/day of NYT (TJ-108, Tsumura and Co., see STORK http://mpdb.nibiohn.go.jp/stork/) to allow recovery from anorexia and malnutrition. Because his pulse remained weak and water brash from the stomach to esophagus persisted, indicating qi deficiency, qi counterflow, phlegm, and dampness in the traditional medicine setting, we changed RKT to BRIGHT (TJ-116, Tsumura and Co., see STORK http://mpdb.nibiohn.go.jp/stork/) to treat the persistent anorexia, nausea, vomiting, and anxiety. After taking these two Kampo medicines, his appetite gradually recovered, and nutritional status indicators such as TP, Alb, and body weight gradually increased. His PS improved from 4 to 0, and his anxiety and depressive state also improved, with his body weight returning to 60 kg. Figure 3 shows the clinical course of the treatment.

After the re-administration of nivolumab under Kampo treatment, the patient remained in good condition, with no cancer recurrence.
medicines is pseudoaldosteronism, caused by glycyrrhizin, which is included in several Kampo medicines (Arai et al., 2020). A report of patients with pseudoaldosteronism in Japan showed that even small amounts of licorice (less than 2.0 g) could cause pseudoaldosteronism, and older age is considered a risk factor for the disease (Yoshino et al., 2014).

Table 1 shows the number of crude drugs used in RKT, BRGHT, and NYT. The combination of BRGHT and NYT includes almost all the crude RKT drugs in large amounts. In addition, crude drugs that promote gastrointestinal movement are added. However, the amount of licorice is limited to 1.0 g per day, and pseudoaldosteronism can be avoided. Thus, we switched to BRGHT and NYT for recovery from anorexia and nausea.

BRGHT, composed of nine crude drugs, is a Kampo medicine used to treat nausea and anxiety. Further, 7.5 g of TJ-116 BRGHT includes the crude drugs shown in Tables 1, 2 (STORK, http://mpdb.nibiohn.go.jp/stork/). We previously reported that BRGHT could inhibit corticotropin-releasing hormone receptor 2, dopamine receptors D2 and D3, neuropeptide Y receptor type 2, and acetylcholinesterase, which synergistically improves gastric emptying (Mogami et al., 2020). BRGHT administration also reduces the frequency of aspiration pneumonia in patients with brain damage (Takayama et al., 2021).

NYT is a Kampo medicine, composed of 12 crude drugs, used to recover from disease, fatigue, and anorexia. Additionally, 9.0 g of TJ-108 NYT includes the crude drugs shown in Tables 1, 2 (STORK, http://mpdb.nibiohn.go.jp/stork/). A review of RCTs of NYT demonstrated the usefulness of NYT in the treatment of cancer and related conditions (Usayama et al., 2019). Other studies have reported increased food intake via the activation of orexigenic OX1R-expressing neurons in the hypothalamus (Miyano et al., 2020), maintenance of nutritional status in patients with wasting conditions (Sasatani et al., 2020), and the activation of both ghrelin-responsive and ghrelin-unresponsive neuropeptide Y pathways for the treatment of anorectic conditions, which are associated with cancer or frailty (Goswami et al., 2019). These studies support the potential of NYT in cancer patients with anorexia, malnutrition, and mental disorders.

RKT is also used to treat chemotherapy-induced anorexia. The mechanisms of appetite improvement through ghrelin signaling have been reported in several studies (Asakawa et al., 2001; Nakazato et al., 2001; Takeda et al., 2008). Yoshiya et al. (2020) reported that RKT could mitigate chemotherapy-induced anorexia and ameliorate acylated ghrelin levels in the plasma, decreasing anorexia during the delayed phase of cisplatin-based chemotherapy in cancer patients.

RKT is used to improve nausea and anorexia via ghrelin signaling, while NYT is used to improve anorexia, malnutrition, and anxiety. BRGHT improves both upper gastrointestinal motility via multiple signaling (D2, D3, neuropeptide Y, and acetylcholinesterase) and anxiety. Over 60% of metastatic melanoma survivors treated with ICIs experience anxiety while waiting for test results, fear of recurrence, and death (Lai-Kwon et al., 2019). Anxiety could result in appetite loss, gastrointestinal impairment, and malnutrition. The patient in the presented case may have had anxiety because of metastatic melanoma and long-term chemotherapy. Therefore, the combination of NYT and BRGHT would be more effective for improving malnutrition, upper gastrointestinal dysfunction, and anxiety. According to the reports above and the present case, the combined use of BRGHT and NYT allows recovery from appetite loss, nausea, and malnutrition during cancer treatment.
### TABLE 1 | Amounts of crude drugs in Kampo medicines, RKT, BRGHT, and NYT (top of the table); and symptoms and conditions of application (bottom).

| Crude Drugs | RTK (TJ-43) | BRGHT (TJ-116) | NYT (TJ-108) | BRGHT (TJ-116) with NYT (TJ-108) |
|-------------|-------------|----------------|--------------|----------------------------------|
| JP Ginseng  | 4.0 g       | 3.0 g          | 3.0 g        | 6.0 g                            |
| JP Atractylodes lancea rhizome | 4.0 g | 4.0 g | — | 4.0 g |
| JP Atractylodes rhizome | — | — | 4.0 g | 4.0 g |
| JP Citrus unshiu peel | 2.0 g | 3.0 g | 2.0 g | 5.0 g |
| JP Poria sclerotium | 4.0 g | 5.0 g | 4.0 g | 9.0 g |
| JP Ginger | 0.5 g | 1.0 g | — | 1.0 g |
| JP Pinellia tuber | 4.0 g | 6.0 g | — | 6.0 g |
| JP Glycyrrhiza | 1.0 g | — | 1.0 g | 1.0 g |
| JP Jujube | 2.0 g | — | — | — |
| JP Magnolia bark | — | 4.0 g | — | 4.0 g |
| JP Peperis herb | — | 2.0 g | — | 2.0 g |
| JP Immature orange | — | 1.5 g | — | 1.5 g |
| JP Japanese angelica root | — | — | 1.5 g | 1.5 g |
| JP Astragalus root | — | — | 4.0 g | 4.0 g |
| JP Rehmannia root | — | — | 4.0 g | 4.0 g |
| JP Cinnamon bark | — | — | 2.5 g | 2.5 g |
| JP Polygala root | — | — | 2.0 g | 2.0 g |
| JP Peony root | — | — | 2.0 g | 2.0 g |
| JP Schisandra fruit | — | — | 1.0 g | 1.0 g |

Symptoms and conditions of application:
- Weak stomach, loss of appetite, full stomach pit, fatigue, anemia, cold limbs
- Gastritis, gastric atony, gastropitosis, malabsorption, anorexia, gastric pain, and vomiting
- Depressed feelings, feeling of foreign body in the throat and esophagus
- Palpitation, dizziness, nausea, heartburn, decreased urine volume, anxiety neurosis, nervous gastritis, and hyperemesis gravidarum
- Water brash and gastritis
- Declined constitution after recovery from disease, fatigue, malaise, anorexia, perspiration during sleep, cold limbs, and anemia

### TABLE 2 | Plant names and part of each ingredient described in the present study.

| Ingredient in English | Plant name (Latin) | Plant part (Latin) |
|----------------------|-------------------|-------------------|
| JP Atractylodes Lancea Rhizome | Atractylodes lancea De Candolle, or Atractylodes chinensis Koidzumi Compositae | Rhizoma |
| JP Atractylodes rhizome | Atractylodes japonica Koidzumi ex Kitamura or Atractylodes macrocephala Koidzumi (Atractylodes ovata De Candolle) (Compositae) | Rhizoma |
| JP Cinnamon bark | Cinnamomum cassia Blume (Lauraceae) | Cortex |
| JP Citrus unshiu peel | Citrus unshiu Marcowicz, or Citrus reticulata Blanco (Rutaceae) | Pericarpium |
| JP Ginger | Zingiber officinale Roscoe (Zingiberaceae) | Rhizoma |
| JP Ginseng | Panax ginseng C. A. Meyer (Araliaceae) | Radix |
| JP Glycyrrhiza | Glycyrrhiza uralensis Fischer, or Glycyrrhiza glabra Linné Leguminosae | Radix |
| JP Immature orange | Citrus aurantium Linné var. daidai Makino, Citrus aurantium Linné, or Citrus natsudaidai Hayata | Fructus immaturas |
| JP Japanese angelica root | Angelica acutiloba Kitagawa, or Angelica acutiloba Kitagawa var. sugiyamae Hikino (Umbelliferae) | Radix |
| JP Jujube | Zizyphus jujuba Millar var. inermis Rehder (Pharmaceae) | Fructus |
| JP Magnolia bark | Magnolia obovata Thunberg (Magnolia hypoleuca Siebold et Zuccarin), Magnolia officinalis Rehder et Wilson, or Magnolia officinalis Rehder et Wilson var. bibloa Rehder et Wilson (Magnoliaceae) | Cortex |
| JP Peperis herb | Perilla frutescens Britton var. crispa W. Deane (Labiatae) | Herba |
| JP Pinellia tuber | Pinellia ternata Breitenbach (Araceae) | Tuber |
| JP Polygala root | Polygala tanaceto Wildenow (Polygalaceae) | Radix |
| JP Poria sclerotium | Polyporus cocos Ryvarden et Gilbertson (Poria cocos Wolf) (Polyporaceae) | — |
| JP Schisandra fruit | Schisandra chinensis Ballon (Schisandraceae) | Fructus |
Interstitial lung disease (ILD) or interstitial pneumonitis (IP) are important adverse events of ICIs. The occurrence rate of these adverse events is reported as 7.2% for nivolumab with ipilimumab (Opdivo, 2020). In the present case, computed tomography and blood sampling did not show the existence of ILD or IP. The ILD or IP occurrence rate with RKT has been reported to be 0% (Suzuki et al., 2020), and with NYT and BRGHT, it has never been reported. However, the other Kampo medicine has been reported as a possible cause of ILD or IP (Arai et al., 2020); hence, when using Kampo medicine together with ICIs, careful follow-up for adverse events is recommended.

We believe the improvement of anorexia and malnutrition is related to the use of Kampo medicine; however, cancer remission is also a reason for the patient’s recovery.

CONCLUSION

In a patient with advanced malignant melanoma, cancer was treated using ICIs. Side effects such as anorexia and nausea with poor nutritional status were resolved using Kampo medicines, BRGHT and NYT. The clinical course of the patient in our report shows the usefulness of Kampo medicine as supportive care for symptom relief and the maintenance of nutritional and mental status during cancer treatment.

PATIENT PERSPECTIVE

This case report was approved by the ethics committee of the Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan, on 7 February 2022 (protocol identification number: No. 24377).

REFERENCES

Arai, I., Harada, Y., Koda, H., Tsutani, K., and Motoo, Y. (2020). Estimated Incidence Per Population of Adverse Drug Reactions to Kampo Medicines from the Japanese Adverse Drug Event Report Database (JADER). Traditional Kampo Med. 7, 3–16. doi:10.1002/tkm2.1234

Asakawa, A., Inui, A., Kaga, T., Yuzuruha, H., Nagata, T., Ueno, N., et al. (2001). Ghrelin is an Appetite-Stimulatory Signal from Stomach with Structural Resemblance to Motilin. Gastroenterology 120, 337–345. doi:10.1053/gast.2001.22158

Goswami, C., Dezaki, K., Wang, L., Inui, A., Seino, Y., and Yada, T. (2019). Ninjin-yoeito Activates Ghrelin-Responsive and Unresponsive NPY Neurons in the Arcuate Nucleus and Counteracts Cisplatin-Induced Anorexia. Neuropeptides 75, 58–64. doi:10.1016/j.npep.2019.03.001

Ito, A., Munakata, K., Imazu, Y., and Watanabe, K. (2012). First Nationwide Attitude Survey of Japanese Physicians on the Use of Traditional Japanese Medicine (Kampo) in Cancer Treatment. Evid. Based Complement. Alternat Med. 2012, 957082. doi:10.1155/2012/957082

JAPIC (2014). Kampo Medicine Was Used to Control Cancer-Related Symptoms [Application of Kampo Medicines for the Palliation of Cancer Cachexia. Available at: https://pincs.japic.or.jp/pdf/newPINS/00069048.pdf (Accessed January 5, 2022).

Lai-Kwon, J., Khoo, C., Lo, S., Milé, D., Mohamed, M., Raleigh, J., et al. (2019). The Survivorship Experience for Patients with Metastatic Melanoma on Immune Checkpoint and BRAF-MEK Inhibitors. J. Cancer Surviv 13, 503–511. doi:10.1007/s11766-019-00770-0

Miyano, K., Ohshima, K., Suzuki, N., Furuya, S., Yoshida, Y., Nonaka, M., et al. (2020). Japanese Herbal Medicine Ninjin-yoeito Mediates its Orexigenic Properties Partially by Activating Orexin 1 Receptors. Front. Nutr. 7, 5. doi:10.3389/fnut.2020.00005

Mogami, S., Arita, R., Nahata, M., Fujisuka, N., Takayama, S., and Ishii, T. (2020). Usefulness of a Kampo Medicine on Stress-Induced Delayed Gastric Emptying in Mice. Evid. Based Complement. Alternat Med. 2020, 3797219. doi:10.1155/2020/3797219

Motoo, Y., Arai, I., Kogure, T., and Tsutani, K. (2021). Review of the First 20 Years of the Evidence-Based Medicine Committee of the Japan Society for Oriental Medicine. Traditional Kampo Med. 88, 121–129. doi:10.1002/tkm2.1279

Nakazono, T., Murakami, N., Date, Y., Koijima, M., Matsuo, H., Kahgawa, K., et al. (2001). A Role for Ghrelin in the central Regulation of Feeding. Nature 409, 194–198. doi:10.1038/3501587

Opdivo (2020). Guide for Proper Use in Nivolumab with Iplimumab. Available at: https://www.opdivo.jp/file-download/download/private/6211.

Sasatani, Y., Okauchi, S., Ohara, G., Kagohashi, K., and Satoh, H. (2020). Long-term Maintenance of Nutritional Status with Ninjin-yoeuto in Terminal Patients with Chronic Respiratory Disease: Two Case Reports. Biomed. Rep. 12, 121–124. doi:10.3892/br.2019.1267

Shimizu, M., Takayama, S., Kikuchi, A., Arita, R., Ono, R., Ishizawa, K., et al. (2021). Integrative Therapy for Advanced Pancreatic Cancer Using Kampo and Western Medicine: A Case Report. Explore (NY) 17, 255–258. doi:10.1016/j.explore.2020.07.003

Shimizu, M., Takayama, S., Kikuchi, A., Arita, R., Ono, R., Ishizawa, K., et al. (2021a). Kampo Medicine Treatment for Advanced Pancreatic Cancer: A Case Report. Evid. Based Complement. Alternat Med. 2021, 88, 221–228. doi:10.1002/tkm2.1293

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

This case report was approved by the ethical committee of the Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

ST treated the patient and wrote the manuscript. RA created the tables, and TI provided suggestions regarding the manuscript.

FUNDING

This study was supported by the Tsumura and Co., a pharmaceutical company in Kampo medicines in Japan.

ACKNOWLEDGMENTS

We would like to thank Akiko Kuwabara for clinical research coordination.
Suzuki, S., Takayama, S., Kikuchi, A., Arita, R., Abe, M., Saito, R., et al. (2021). Orengedokuto and Shosaikoto for Intractable Intracranial Carmustine Implant-Induced Fever in a Patient with Brain Tumor: A Case Report. Explore (NY) 17, 236–238. doi:10.1016/j.explore.2020.08.014
Suzuki, Y., Hisada, T., Miura, T., Matsumoto, Y., and Kajima, Y. (2020). Adverse Drug Reaction Frequency Investigation of TSUMURA Rikkunshito Extract Granules for Ethical Use. Prog. Med. 40, 305–314.
Takayama, S., Arita, R., Ohsawa, M., Kikuchi, A., Yasui, H., Makino, T., et al. (2019). Perspectives on the Use of Ninjin’yōeito in Modern Medicine: A Review of Randomized Controlled Trials. Evid. Based Complement. Alternat Med. 2019, 9590260. doi:10.1155/2019/9590260
Takayama, S., Arita, R., Kikuchi, A., and Ishii, T. (2021). Bukuryoingohangekobokuto May Improve Recurrent Aspiration Pneumonia in Patients with Brain Damage and Reduce the Caregiver burden. J. Fam. Med Prim Care 10, 558–560. doi:10.4103/jfmpc.jfmpc_1627_20
Takayama, S., and Ishii, T. (2022). Kampo Medicine Bukuryoingohangekobokuto and Ninjin’yōeito yōeito as Supportive Care for Management of Anorexia and Tightness of the Esophagus in Advanced Esophageal Cancer: A Case Report. Explore (NY), 1–4. doi:10.1016/j.explore.2022.02.007
Takeda, H., Sadakane, C., Hattori, T., Katsurada, T., Ohkawara, T., Nagai, K., et al. (2008). Rikkunshito, an Herbal Medicine, Suppresses Cisplatin-Induced Anorexia in Rats via 5-HT2 Receptor Antagonism. Gastroenterology 134, 2008–2013. doi:10.1053/j.gastro.2008.02.078
Yoshino, T., Yanagawa, T., and Watanabe, K. (2014). Risk Factors for Pseudoaldosteronism with Rhabdomyolysis Caused by Consumption of Drugs Containing Licorice and Differences between Incidence of These Conditions in Japan and Other Countries: Case Report and Literature Review. J. Altern. Complement. Med. 20, 516–520. doi:10.1089/acm.2013.0454
Yoshiya, T., Mimae, T., Ito, M., Sasada, S., Toutani, Y., Satoh, K., et al. (2020). Prospective, Randomized, Cross-Over Pilot Study of the Effects of Rikkunshito, a Japanese Traditional Herbal Medicine, on Anorexia and Plasma-Acylated Ghrelin Levels in Lung Cancer Patients Undergoing Cisplatin-Based Chemotherapy. Invest. New Drugs 38, 485–492. doi:10.1007/s10637-019-00836-x

Conflict of Interest: All authors belong to the Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine, a joint research course with TSUMURA and Co., a pharmaceutical company of Kampo medicines in Japan.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Takayama, Arita and Ishii. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.